Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients

Phase 3

Conditions: Esophagus Cancer
Chemotherapy Effects

Interventions: Drug: Docetaxel
Drug: Fluorouracil
Drug: Cisplatin

First Posted Date: 2016-12-23

Last Posted Date: 2016-12-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 358

Registration Number: NCT03002064

Locations: 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study

Phase 3

Recruiting

Conditions: Stage IV Colorectal Cancer AJCC v7
Metastatic Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-12-20

Last Posted Date: 2024-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 120

Registration Number: NCT02997228

Locations: 🇺🇸
Northwell Health/Center for Advanced Medicine, Lake Success, New York, United States
🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸
University of Rochester, Rochester, New York, United States

and more 443 locations

Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Neoplasm
Chemoradiation

Interventions: Drug: Fluorouracil
Drug: Docetaxel

First Posted Date: 2016-11-21

Last Posted Date: 2016-11-21

Lead Sponsor: Zhu Yujia

Target Recruit Count: 120

Registration Number: NCT02969473

Locations: 🇨🇳
SYSU Cancer Center, Guangzhou, Guangdong, China

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: pembrolizumab
Drug: trastuzumab
Drug: capecitabine
Drug: cisplatin
Drug: Oxaliplatin
Drug: 5-Fluorouracil

First Posted Date: 2016-11-03

Last Posted Date: 2023-03-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT02954536

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 5 locations

FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients

Phase 3

Conditions: Colorectal Carcinoma

Interventions: Drug: Irinotecan
Drug: 5-fluorouracil
Drug: Leucovorin

First Posted Date: 2016-10-17

Last Posted Date: 2016-10-17

Lead Sponsor: Fudan University

Target Recruit Count: 164

Registration Number: NCT02935764

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Phase 3

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Irinotecan
Drug: regorafenib
Drug: Folinic Acid
Drug: 5-FU
Drug: Bevacizumab
Drug: Cetuximab
Drug: Capecitabine
Drug: Irinotecan 125mg
Drug: Cetuximab wkly

First Posted Date: 2016-10-17

Last Posted Date: 2023-11-15

Lead Sponsor: Ludwig-Maximilians - University of Munich

Target Recruit Count: 673

Registration Number: NCT02934529

Locations: 🇩🇪
Klinikum der Universitaet Muenchen - Campus Grosshadern, Munich, Germany

Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions: Drug: Encorafenib
Drug: Binimetinib
Drug: Irinotecan
Drug: Cetuximab
Drug: Folinic Acid
Drug: 5-Fluorouracil

First Posted Date: 2016-10-10

Last Posted Date: 2023-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 702

Registration Number: NCT02928224

Locations: 🇺🇸
The University of Kansas Cancer Center, Investigational Drug Services, Westwood, Kansas, United States
🇧🇷
Hospital do Olho, Salvador, Bahia, Brazil
🇦🇹
DZU, Diagnose Zentrum Urania GmbH, Wien, Austria

and more 404 locations

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Stage III Rectal Cancer AJCC v7
Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Fluorouracil
Radiation: Intensity-Modulated Radiation Therapy
Drug: Leucovorin
Drug: Oxaliplatin
Biological: Pembrolizumab
Drug: Veliparib

First Posted Date: 2016-10-03

Last Posted Date: 2024-04-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 363

Registration Number: NCT02921256

Locations: 🇺🇸
Island Urology, Honolulu, Hawaii, United States
🇺🇸
Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸
Straub Clinic and Hospital, Honolulu, Hawaii, United States

and more 645 locations

Nordic Pancreatic Cancer Trial (NorPACT) - 1

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Procedure: Pancreatic surgery
Drug: 5-FU
Drug: Oxaliplatine
Drug: Irinotecan

First Posted Date: 2016-09-29

Last Posted Date: 2024-11-20

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 140

Registration Number: NCT02919787

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark
🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇳🇴
Haukeland University Hospital, Bergen, Norway

and more 10 locations

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Phase 3

Active, not recruiting

Conditions: Lynch Syndrome
DNA Repair Disorder
Colon Adenocarcinoma
Stage III Colon Cancer AJCC v8

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Other: Quality-of-Life Assessment

First Posted Date: 2016-09-23

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 700

Registration Number: NCT02912559

Locations: 🇺🇸
Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States
🇺🇸
Macomb Hematology Oncology PC, Warren, Michigan, United States
🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States

and more 1047 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy